|
|
| | MK-8353 Basic information |
| Product Name: | MK-8353 | | Synonyms: | MK-8353;SCH-900565;SCH900353;MK-8353 (SCH900353);3-Pyrrolidinecarboxamide, 1-[2-[3,6-dihydro-4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-1(2H)-pyridinyl]-2-oxoethyl]-N-[3-[6-(1-methylethoxy)-3-pyridinyl]-1H-indazol-5-yl]-3-(methylthio)-, (3S)-;SCH 900353,Extracellular signal regulated kinases,Inhibitor,inhibit,MK 8353,SCH-900353,MK-8353,ERK,MK8353;(S)-N-(3-(6-Isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide;SCH900353 (MK-8353) | | CAS: | 1184173-73-6 | | MF: | C37H41N9O3S | | MW: | 691.84 | | EINECS: | | | Product Categories: | | | Mol File: | 1184173-73-6.mol |  |
| | MK-8353 Chemical Properties |
| density | 1.36±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | Soluble in DMSO | | pka | 11.89±0.40(Predicted) | | form | Solid | | color | Off-white to light brown |
| | MK-8353 Usage And Synthesis |
| Definition | ChEBI: MK-8353 is a member of the class of indazoles that is 1H-indazole substituted by a 6-(propan-2-yloxy)pyridin-3-yl group at position 3 and by a {[(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)pyrrolidin-3-yl]carbonyl}amino group at position 5. It is a potent and selective inhibitor of ERK1 and ERK2 in vitro (IC50 values of 23.0 nM and 8.8 nM, respectively). The drug is being developed by Merck Sharp & Dohme and is currently in clinical development for the treatment of advanced/metastatic solid tumors. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a member of indazoles, a member of triazoles, a dihydropyridine, a member of pyridines, an aromatic ether, a secondary carboxamide, a pyrrolidinecarboxamide, a N-alkylpyrrolidine, a methyl sulfide and a tertiary carboxamide. |
| | MK-8353 Preparation Products And Raw materials |
|